Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : Statement on Supply of its Single-shot COVID-19 Vaccine

06/11/2021 | 02:09pm EDT

New Brunswick, N.J., June 11, 2021 - Johnson & Johnson confirms the United States Food & Drug Administration (FDA) has authorized two batches of drug substance, manufactured at the Emergent BioSolutions, Inc. Bayview facility, under the Emergency Use Authorization (EUA) for its single-shot COVID-19 vaccine.

'Since establishing our COVID-19 vaccine program, Johnson & Johnson has committed to producing safe, high-quality vaccines in order to bring health and hope to people everywhere,' said Kathy Wengel, Executive Vice President and Chief Global Supply Chain Officer, Johnson & Johnson. 'Today's decisions represent progress in our continued efforts to make a difference in this pandemic on a global scale, and we appreciate the close collaboration with the FDA and global health authorities.'

The Company continues to substantially expand its global vaccine manufacturing network as we work with regulatory and health authorities to supply our COVID-19 vaccine worldwide.

As COVID-19 continues to impact countries and cause untold suffering worldwide, our commitment has never been stronger to contribute to a global solution to this public health crisis. We believe that a single-shot, easy to distribute COVID-19 vaccine is an essential tool to combat the pandemic globally.

Cautions Concerning Forward-Looking Statements
This press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995 regarding development of a potential preventive vaccine for COVID-19. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Janssen Pharmaceutical Companies, and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned 'Cautionary Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in the company's most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

###

Disclaimer

Johnson & Johnson published this content on 11 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 June 2021 18:08:05 UTC.


ę Publicnow 2021
All news about JOHNSON & JOHNSON
06/21JOHNSON & JOHNSONá : How Johnson & Johnson Helped Us Adopt 11 Children
AQ
06/19MODERNAá : U.S. administers more than 317 mln doses of COVID-19 vaccines - CDC
RE
06/18The Week Ahead -- Barron's
DJ
06/17JOHNSON & JOHNSONá : Eying border reopening, Mexico begins J&J vaccine rollout i..
AQ
06/17Canada Vaccine Panel Recommends Against AstraZeneca PLC for Second Dose
DJ
06/17US to Spend $3.2 Billion on COVID Treatments Research
MT
06/16ASTRAZENECAá : Second Phase of Covid-19 Vaccinations Begins
AQ
06/16EU Says Johnson & Johnson May Not Meet Vaccine Supply Commitment After Jabs C..
MT
06/15US, EU Vow to Provide COVID-19 Vaccine to Two-Thirds of World's Population by..
MT
06/15JOHNSON & JOHNSONá : Aspen to Dispatch 300 000 J&J Vaccines for Teachers
AQ
More news
Financials (USD)
Sales 2021 92 812 M - -
Net income 2021 22 227 M - -
Net Debt 2021 314 M - -
P/E ratio 2021 19,8x
Yield 2021 2,55%
Capitalization 431 B 431 B -
EV / Sales 2021 4,65x
EV / Sales 2022 4,35x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 183,67 $
Last Close Price 163,84 $
Spread / Highest target 24,5%
Spread / Average Target 12,1%
Spread / Lowest Target -3,56%
EPS Revisions
Managers and Directors
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON4.10%431 456
ROCHE HOLDING AG12.99%328 650
PFIZER, INC.7.09%220 661
NOVARTIS AG3.00%210 615
ABBVIE INC.7.07%202 639
ELI LILLY AND COMPANY29.44%202 413